RE
NTLA icon

RBC Europe’s Intellia Therapeutics NTLA Stock Holding History

RBC Europe’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-285
Closed -$5.67K – 1171
2020
Q3 		$5.67K Hold
285
– – ﹤0.01% 892
2020
Q2 		$5.99K Hold
285
– – ﹤0.01% 848
2020
Q1 		$3.49K Hold
285
– – ﹤0.01% 858
2019
Q4 		$4.18K Hold
285
– – ﹤0.01% 913
2019
Q3 		$3.81K Hold
285
– – ﹤0.01% 920
2019
Q2 		$4.67K Hold
285
– – ﹤0.01% 921
2019
Q1 		$4.87K Hold
285
– – ﹤0.01% 932
2018
Q4 		$3.89K Hold
285
– – ﹤0.01% 945
2018
Q3 		$8.16K Hold
285
– – ﹤0.01% 885
2018
Q2 		$7.8K Buy
+285
New +$6.9K ﹤0.01% 898

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVAX
Atlas Venture Associates XI Cambridge, Massachusetts $631M AUM

RBC Europe's NTLA Position: Q4 2020 in Review

RBC Europe sold out of Intellia Therapeutics (NTLA) in Q4 2020, closing a stake of 285 shares — an estimated $5.67K sold.

RBC Europe first reported a position in NTLA in Q2 2018 and held it in 10 quarters. The position peaked at $8.16K in Q3 2018. 240 funds tracked by Wall St. Rank hold NTLA as of Q4 2020.

  • RBC Europe reported no remaining Intellia Therapeutics position as of Q4 2020 after selling out during the quarter.
  • RBC Europe sold 285 Intellia Therapeutics shares in Q4 2020, an estimated $5.67K.
  • RBC Europe first reported a position in Intellia Therapeutics in Q2 2018 and held it in 10 quarters.
  • RBC Europe's Intellia Therapeutics position peaked at $8.16K in Q3 2018.
  • 240 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2020.

Based on RBC Europe's 13F filing for Q4 2020, filed 9 Nov 2023.